^
    Back
    Association details:
    Biomarker:SDC1 elevation
    Cancer:Multiple Myeloma
    Drug:lenalidomide (TNFα inhibitor, IL-6 inhibitor, IL-12 inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    ASH 2020
    Title:

    Serum Soluble Syndecan-1 (ssCD138) Can Contribute to the Discrimination of Lenalidomide Resistant Multiple Myeloma (MM) Patients

    Published date:
    11/04/2020
    Excerpt:
    Patients with High ssynd-1 levels at RD initiation presented shorter LenPFS 2 (p=0,011) and TNT (p=0,018)….These results suggest that soluble syndecan-1 levels can discriminate patients at risk to the lenalidomide resistant early.
    Secondary therapy:
    dexamethasone